Re: What's the deal with Zenith?
in response to
by
posted on
Jun 23, 2023 09:31AM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
tada ... isn't Hepa in for up to 50% of the trial (Asian portion)? That would obviously help keep RVX's costs and Zenith loan amount down?
If BoM2 fails, then Zenith either reabsorbs RVX IP and assets (certainly worth $40m, even with BoM2 failure?), ... or sells off RVX assets for loan recovery?
I know some will ask what would RVX assets even be worth if/after another P3 failure (BoM2)?
A lot in my mind, unless BoM2 shows ABL to be a complete and utter failure. Unlikely based on what we learned from BoM. Even with previous study misses, we have always come out of them with great ad hoc learning data, to study and evaluate and hone in on certain concepts a little better. We are still somewhere in that process, and seemingly getting closer to pinpointing the correct combinations and concepts. RVX may not have a life after a failed BoM2, but the the technology will live on, somewhere, for continued study and eventual application. And have a value.
Remember, ABL has not been shown to be a failure. It just hasn't met approvable standards yet, and that is just a matter of honing in on the mechanisms, and proper endpoints and certain pre-defined metrics.
BoM2 looks very promising, at this point in our learning. And even if it fails, Zenith would have good recourse and value. And the royalty shares are worthless anyway, without RVX success.
No brainer? ... especially if one of the interested BP's already working with Zenith, wants to get more deeply involved and believes in the RVX/ABL science and data also? Possibly with an interest in purchasing the whole kit-n-kaboodle down the road, if things keep progressing favorably?
All speculation and wishful thinking on my part, but this all makes sense to me as a way toward success, even if complicated ... just looking at the landscape, and reading into Don's presentation also, ... which seemed very deal centric (good!!), Zenith powered (makes sense), and with a targeted look at BP's with high revenue patents expiring (yes sir, target rich environment!) ...
And there is also the possibility of generating revenues in the middle east next year also, via EUA to help get some revenues going, while waiting on BoM2 (and repay loans/debts/obligations) ... Morocco and the M.E. keeps popping up.
I like it, smart approach, if "doable" ... need one of the Zenith BP's to pop for RVX future royalty streams though, and also get further down the partnering rabbit hole with Zenith/RVX. Who will it be?